AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03344211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03344211 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium Ra 223 Dichloride
Description: Given IV
Study NCT04087811 — intervention group
Intervention type: DEVICE
Intervention: Superion® Indirect Decompression System (IDS)
Description: Superion® Indirect Decompression System (IDS) (Superion® implant)
Study NCT00652769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial or Endoscopic Ultrasound
Description: Patients with anterior mediastinal or subcarinal disease will undergo EBUS. Patients with posterior, subcarinal or AP window disease will undergo EUS. Patients with no mediastinal disease on CT scan will undergo EBUS.
Study NCT00652769 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy, CT-guided biopsy, PET scan, Mediastinoscopy
Description: Investigations will be determined by the multi-disciplinary team responsible for the patient
Study NCT06242769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stannous Fluoride Toothpaste (SnF)
Description: test
Study NCT06242769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stannous Fluoride Toothpaste (SnF)
Description: test
Study NCT06242769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Fluoride Toothpaste (CDC)
Description: negative control
Study NCT06242769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colgate Fluoride Toothpaste (CDC)
Description: negative control
Study NCT00218608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disulfiram
Description: Disulfiram at 0, 62.5, 125 and 250 mg/day were administered during weeks 3-14
Study NCT00218608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Disulfiram
Description: Disulfiram at 0, 62.5, 125 and 250 mg/day were administered during weeks 3-14
Study NCT02847429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib
Study NCT02847429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01720576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033 (SAR391786)
Study NCT02690012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Oxide
Description: Magnesium Oxide
Study NCT02690012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Citrate
Description: Magnesium Citrate
Study NCT01720576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00807885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hylenex-facilitated subcutaneous Lactated Ringer's infusion
Description: single subcutaneous 150 U dose of hylenex, followed by subcutaneous infusion of 1000 mL Lactated Ringer's solution
Study NCT04747600 — intervention group
Intervention type: PROCEDURE
Intervention: surgical resection
Description: surgical resection
Study NCT02724852 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 ml of MMR vaccine
Description: Participants in each arm received the same vaccine, a 0.5 ml of MMR vaccine at deltoid region
Study NCT02724852 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 ml of MMR vaccine
Description: Participants in each arm received the same vaccine, a 0.5 ml of MMR vaccine at deltoid region
Study NCT02438553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OSTNS Neurostimulator
Description: Non-invasive transcutaneous neurostimulation.
Study NCT02438553 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo OSTNS Neurostimulator
Description: Placebo non-invasive transcutaneous neurostimulation
Study NCT03065075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenazopyridine
Description: Phenazopyridine 200 mg on morning of postoperative day 1
Study NCT00150878 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conditioning therapy
Description: Preparation before allogeneic transplantation
Study NCT00150878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditioning therapy
Description: Preparation before allogeneic transplantation
Study NCT02469103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C2
Description: C2 and colonoscopy will be performed one after another on the same day
Study NCT02469103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy
Study NCT00810069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine Hydrochloride
Description: Flexible dose of 60 or 120 mg daily
Study NCT00810069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 10 mg in both Early and Delayed Intervention. Flexible dose of 10 to 20 mg daily in Delayed Intervention.
Study NCT04691219 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mulberry leaves powder
Description: Dried powder of mulberry leaves crude extract containing 12 mg of DNJ will be packed in a sealed packet with light and moisture protection. Participants will be instructed to mix 1 packet of the powder with a half glass (approximately 120 mL) of plain water and ingest thrice daily before meals. Additionally, they will be informed to rinse the glass with more water and drink to ensure that all of the powder will be taken.
Study NCT00561431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose of dialysis
Description: Continuous Venovenous Hemodiafiltration (CVVHDF) effluent dose of 20 ml/kg/hr
Study NCT00561431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High dose of dialysis
Description: Continuous Venovenous Hemodiafiltration (CVVHDF) effluent rate 35 ml/kg/hr
Study NCT01682772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Until objective disease progression, unacceptable toxicity or patient withdrawal for whatever reason
Study NCT03471546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care
Description: Initial consultation and follow-up with a palliative care provider
Study NCT02423889 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT04691219 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diet control
Description: Participants will be requested for diet control. They will be asked for attending the diet control program, maintaining diet pattern throughout the study period, and recording a 3-day food record. Individual counseling and assessment of compliance will be performed by licensed dietitians every 4 weeks. Diet control is principally based on carbohydrate counting.
Study NCT04691219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet control
Description: Participants will be requested for diet control. They will be asked for attending the diet control program, maintaining diet pattern throughout the study period, and recording a 3-day food record. Individual counseling and assessment of compliance will be performed by licensed dietitians every 4 weeks. Diet control is principally based on carbohydrate counting.
Study NCT01466413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tropoelastin
Description: Multiple intradermal implants comprising of three treatments, 3 weeks apart, each consisting of 16 injections in total, each 10mm apart in a grid formation over a 3cm x 3cm area of the mid to deep dermis of the medial aspect of the upper arm. Each injection will consist of 20-30ul of product delivered using a 30Gx¼ needle. Each subject will also receive Restylane® Vital Light (control) to the opposite arm following the same treatment regimen and using the same technique. The treatment will be administered on Day 1, 22 and 43.
Study NCT02862964 — intervention group
Intervention type: OTHER
Intervention: identify L4/L5
Description: * For each participant, a provider will first attempt to identify the L4/L5 space using the traditional technique of palpating the iliac crests to estimate spinal level. The provider will mark this space on the person's back with a single dot from a marking pen. The provider will then use the Accuro to again attempt to identify the L4/L5 interspace and mark this point with two dots.~* The participant will then be taken into the fluoroscopy suite for their scheduled procedure a metal instrument will be laid on the skin at the interspace or interspaces that were marked using the palpation and Accuro techniques. Metal instruments show up on fluoroscopy, but the skin markers will not.~* The anesthesiology attending in the fluoroscopy suite will then confirm the true interspace position of these marks under fluoroscopy performed for the standard of care procedure
Study NCT04708080 — intervention group
Intervention type: PROCEDURE
Intervention: thoracic epidural analgesia
Description: A thoracic epidural catheter is routinely placed in patients undergoing open heart surgery in our hospital, at least 1 hour before heparin administration during the operation. After standard monitoring (ECG, SpO2, NIBP) is applied to the patients in the operating room, sedoanalgesia is provided with 1-3mg of midazolam and 50-100mcg of fentanyl. Then, by providing sterilization conditions, an epidural catheter is inserted through the T5-T6 interval with Tuohy needle. After confirming the location of the epidural catheter, 25mg / 10ml bupivacaine is administered as a bolus and then 3ml / hour bupivacaine infusion is started from the solution prepared as 3mg / ml and continues until the 48th postoperative hour. On the postoperative 2nd day, the catheter is removed 10-12 hours after LMWH administration and 2-4 hours after UFH, as recommended by the guidelines, paying attention to the anticoagulant administration times applied to the patients.
Study NCT04144959 — intervention group
Intervention type: DEVICE
Intervention: Indigo Aspiration System
Description: Indigo Aspiration System
Study NCT01396889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Echinacea
Description: 0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old
Study NCT01396889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old) for 3 months
Study NCT03895047 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tomographic EEG Neurofeedback Training
Description: EEG-Electrodes are placed on the patients head to record the brain activity, EEG-recordings are processed by the standardized Low Resolution Brain Electromagnetic Tomography algorithm (sLORETA) to calculate the frequency spectrum in the auditory cortex, the insula and the anterior cingulate cortex and deliver feedback for the patient
Study NCT01435759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg
Description: Antidepressant + SPD489 oral, 10 mg, once daily for 8 weeks
Study NCT01435759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg
Description: Antidepressant + SPD489 oral, 30 mg, once daily for 8 weeks
Study NCT01435759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg
Description: Antidepressant + SPD489 oral, 50 mg, once daily for 8 weeks
Study NCT01435759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg
Description: Antidepressant + SPD489 oral, 70 mg, once daily for 8 weeks
Study NCT01435759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antidepressant + Placebo
Description: oral, once daily for 8 weeks
Study NCT03752879 — intervention group
Intervention type: PROCEDURE
Intervention: Fundal Pressure
Description: Fundal Pressure to assist the vaginal delivery to shorten the second stage of labor
Study NCT02541864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth quadruple therapy
Description: pantoprazole 40 mg bid for 14 days, bismuth subcitrate 120 mg qid for 14 days, tetracycline 500 mg qid for 14 days, metronidazole 250 mg qid for 14 days
Study NCT02541864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid therapy
Description: (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days) followed by (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days, clarithromycin 500 mg bid for 7 days, and metronidazole 500 mg bid for 7 days)
Study NCT01526564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcarnitine
Description: Administration of enteric-coated tablets with warm water at half an hour after meals, 1g (2 tablets) each time, 3 times a day, and the interval at or >4 hours for 8 weeks
Study NCT01526564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 t.i.d, two plates per time
Study NCT02342392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Intralesional ranibizumab 0.3 mg/0.03mL injected 1 week before pterygium excision surgery.
Study NCT01679392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Unilateral, single shot, ultrasound-guided, transversus abdominis plane block with 20 ml ropivacaine (7.5 mg/ml)
Study NCT02936843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: 1 gram, 3 times daily by mouth (total of 3 grams daily)
Study NCT02936843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo for Salsalate; 2 Tabets, 3 times daily by mouth (total of 3 grams daily)
Study NCT02190903 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General endotracheal anesthesia
Description: General Anesthesia~Patients randomized to receive general anesthesia induction of anesthesia with intravenous lidocaine, propofol, fentanyl citrate and vecuronium or cisatracurium, following dosing guidelines defined by protocol. Following tracheal intubation, anesthesia will be maintained with sevoflurane in oxygen and air as defined by protocol. End-tidal gas monitoring (for carbon dioxide and sevoflurane) and maintenance, monitoring, and reversal of neuromuscular blockade will be as per HUP and PPMC routine. Immediate postoperative analgesia will be via IV dilaudid dosed intraoperatively as defined by protocol.
Study NCT02190903 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regional (spinal) Anesthesia
Description: Patients randomized to receive spinal anesthesia will undergo spinal blockade using standard techniques and medications dosed as per protocol, and will include hyperbaric bupivicaine or tetracaine, fentanyl citrate, and epinephrine; algorithms for management of spinal-related hypotension will be defined by protocol. Intraoperative sedation will be achieved via continuous intravenous propofol infusion; supplemental oxygen will be provided by nasal cannula or facemask as needed.
Study NCT03293524 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GS010
Description: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). GS010 will be administrated via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) as a single baseline intravitreal injection.
Study NCT03293524 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: GS010
Description: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). GS010 will be administrated via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) as a single baseline intravitreal injection.
Study NCT03293524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a BSS, sterile, apyrogenic solution and used for ocular surgery. The placebo will be administered via intravitreal injection in a volume of 90 μL.
Study NCT02677870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saproterin dihydrochloride
Description: The drug will be given as described in the arm/group descriptions.
Study NCT02677870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saproterin dihydrochloride
Description: The drug will be given as described in the arm/group descriptions.
Study NCT02677870 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet treatment
Description: Patients will maintain a stable, Phe restricted diet (including formula) that is consistent with their diet at the time of enrollment. This will be monitored by food diaries kept for 3 days of each week.
Study NCT02677870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet treatment
Description: Patients will maintain a stable, Phe restricted diet (including formula) that is consistent with their diet at the time of enrollment. This will be monitored by food diaries kept for 3 days of each week.
Study NCT02677870 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet treatment
Description: Patients will maintain a stable, Phe restricted diet (including formula) that is consistent with their diet at the time of enrollment. This will be monitored by food diaries kept for 3 days of each week.
Study NCT02218723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FF UD-DPI
Description: A blister containing a small quantity of powder comprising of a blend of FF (micronised) and excipient(s) will be administered using UD-DPI. It is available in following dosages: 80mcg/Blister (0.8% Blend); 100mcg/Blister (0.8% Blend); 140mcg/Blister (0.8% Blend); 100mcg/Blister (0.6% Blend)
Study NCT02218723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FF ELLIPTA DPI
Description: A blister strip contained within the ELLIPTA device. Each blister contains a small quantity of powder comprising of a blend of FF and excipient(s) in dose 100mcg/Blister (0.8% Blend)
Study NCT00734591 — intervention group
Intervention type: DRUG
Intervention: Exubera
Description: Subjects who had been treated with Exubera in a prior Exubera controlled trial. Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
Study NCT00734591 — intervention group
Intervention type: OTHER
Intervention: Randomized diabetes therapy
Description: Subjects who had been treated with a comparator (other diabetes treatment including one or more of: subcutaneous insulin, sulfonylureas, biguanides, or thiazolinediones) in a prior Exubera controlled trial.~Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
Study NCT02805712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verbal Information and Discussion
Description: Intervention patient will receive a outpatient session with a palliative care social worker in the heart failure clinic two weeks post discharge consent focusing on goals of care.
Study NCT02805712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will receive usual written care material and a palliative care consult if ordered by physician.
Study NCT03064152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotational Thromboelastometry
Description: ROTEM is a point-of-care coagulation assay.
Study NCT02492230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Closure Device (Watchman)
Description: This device is a self-expanding nickel titanium (nitinol) frame structure with fixation barbs and a permeable polyester fabric cover. The device ranges in diameter from 21 mm to 33 mm to accommodate varying LAA anatomy and size. It will be implanted via a trans-septal approach by use of a catheter based delivery system to seal the ostium of the LAA. The implantation will be guided by fluoroscopy and TEE to verify proper positioning and stability. The dose of warfarin will be adjusted to maintain INR 2.0 - 3.0 for 45 days. If TEE data shows no additional flow in LAA, warfarin will be discontinued: Aspirin dose: 75 mg for all period of study; Clopidogrel dose: 75 mg for 6 months after procedure.
Study NCT02492230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin dose adjusted to maintain INR 2.0-3.0 for all period of study; Aspirin dose-75mg for 45 days after randomization; Clopidogrel dose-75mg for 6 months after procedure.~All drugs will be started before PCI procedure. Low molecular weight heparins will be used before procedure and will be stopped when INR reach 1.8-2.0.
Study NCT03839329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Training
Description: Acceptance and Commitment Therapy is an acceptance- and mindfulness-based psychotherapy that aims to foster psychological flexibility.
Study NCT01523145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of twelve weeks) and psychoeducational care (4 sessions over 6 months)
Study NCT01523145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: usual follow-up Standard follow-up at the participating heart center
Study NCT00227539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00227539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Study NCT00227539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00227539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT00227539 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18